CN111991511A - Eye protection cream - Google Patents
Eye protection cream Download PDFInfo
- Publication number
- CN111991511A CN111991511A CN202010916594.6A CN202010916594A CN111991511A CN 111991511 A CN111991511 A CN 111991511A CN 202010916594 A CN202010916594 A CN 202010916594A CN 111991511 A CN111991511 A CN 111991511A
- Authority
- CN
- China
- Prior art keywords
- eye
- component
- percentage
- raw materials
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006071 cream Substances 0.000 title claims abstract description 22
- 239000002674 ointment Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims description 30
- -1 polydimethylsiloxane Polymers 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 11
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 11
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 10
- 230000001804 emulsifying effect Effects 0.000 claims description 10
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 8
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 5
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 5
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 5
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 5
- 241001076416 Dendrobium tosaense Species 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000940 FEMA 2235 Substances 0.000 claims description 5
- 241000244365 Ligusticum sinense Species 0.000 claims description 5
- 239000004264 Petrolatum Substances 0.000 claims description 5
- 241000972673 Phellodendron amurense Species 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 229940116229 borneol Drugs 0.000 claims description 5
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 5
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 5
- 229920006037 cross link polymer Polymers 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 5
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 5
- 239000004744 fabric Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 229930182478 glucoside Natural products 0.000 claims description 5
- 229940075529 glyceryl stearate Drugs 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 5
- 229940041616 menthol Drugs 0.000 claims description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 235000019198 oils Nutrition 0.000 claims description 5
- 239000004006 olive oil Substances 0.000 claims description 5
- 235000008390 olive oil Nutrition 0.000 claims description 5
- 229940066842 petrolatum Drugs 0.000 claims description 5
- 235000019271 petrolatum Nutrition 0.000 claims description 5
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 5
- 235000008160 pyridoxine Nutrition 0.000 claims description 5
- 239000011677 pyridoxine Substances 0.000 claims description 5
- 238000012797 qualification Methods 0.000 claims description 5
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- 229940011671 vitamin b6 Drugs 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 4
- 241001113925 Buddleja Species 0.000 claims description 4
- 244000201986 Cassia tora Species 0.000 claims description 4
- 235000014552 Cassia tora Nutrition 0.000 claims description 4
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 4
- 244000182216 Mimusops elengi Species 0.000 claims description 4
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 4
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 4
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 4
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 2
- 244000042664 Matricaria chamomilla Species 0.000 claims description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 1
- 210000001508 eye Anatomy 0.000 abstract description 30
- 208000003464 asthenopia Diseases 0.000 abstract description 12
- 208000024891 symptom Diseases 0.000 abstract description 6
- 206010013774 Dry eye Diseases 0.000 abstract description 4
- 208000030533 eye disease Diseases 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 abstract description 3
- 239000003755 preservative agent Substances 0.000 abstract description 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 208000030961 allergic reaction Diseases 0.000 abstract description 2
- 235000019606 astringent taste Nutrition 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 230000004438 eyesight Effects 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 230000002335 preservative effect Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 9
- 229940008099 dimethicone Drugs 0.000 description 5
- 230000000116 mitigating effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229940119217 chamomile extract Drugs 0.000 description 3
- 235000020221 chamomile extract Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 229940104256 sodium taurate Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- CNXJITYCNQNTBD-UHFFFAOYSA-L dipotassium;hexadecyl phosphate Chemical compound [K+].[K+].CCCCCCCCCCCCCCCCOP([O-])([O-])=O CNXJITYCNQNTBD-UHFFFAOYSA-L 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002189 macula lutea Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses eye protecting ointment which comprises A, B, C, D, E, F five components. The eye protection cream has the effects of nourishing and moistening eyes, clearing liver and improving eyesight, dispelling wind and resisting inflammation, and promoting blood circulation and removing obstruction in channels, can relieve eye fatigue symptoms such as eye dryness, eye astringency, eye distending pain and the like caused by various eye diseases, and comprehensively care eye health; the eye protection cream disclosed by the invention is convenient to use, does not contain a preservative, is high in applicability, does not cause allergic reaction on any skin, and is mild in use.
Description
Technical Field
The invention belongs to the field of health care and medical treatment, and particularly relates to eye protection cream.
Background
With the popularization of various electronic terminals, visual fatigue becomes a topic of public concern more and more, the visual fatigue is a common eye disease, and the specific symptoms are dry eye, acid swelling, visual double image and intermittent visual blurring, which can cause general symptoms such as nausea, vomiting, dizziness, headache, neck muscle tension, shoulder aching pain and the like in severe cases, thereby reducing the working efficiency of adults, causing the learning disorders of teenagers and children, and directly influencing the work and life of people. Mild asthenopia is usually not paid attention by people, so that asthenopia symptoms are aggravated, and various eye diseases can be caused by long-term repeated asthenopia. Modern medicine considers that the occurrence of asthenopia is related to improper use or overstrain of eye muscles, namely that the eyeball is in a search fixation state for a long time, the metabolism of extraocular muscles and ciliary muscles is increased, the accumulation of metabolic waste such as oxygen free radicals is increased, and the cellular structure is damaged and the function is reduced; secondly, the recovery time of macula lutea and retina is prolonged due to the over consumption of cells and the untimely supply of required nutrients, which leads to the aggravation of asthenopia.
Eye protection products on the market are poor in quality at present, a plurality of products contain preservatives, and eye discomfort symptoms are aggravated after the eye protection products are applied, particularly dry eyes and painful eyes.
Disclosure of Invention
The invention aims to provide an eye cream.
In order to achieve the purpose, the invention adopts the following technical scheme:
an eye-protecting ointment, which comprises A, B, C, D, E, F five components.
The component A comprises the following raw materials in percentage by weight:
0-10% of glycerol, 0-5% of sodium polyacrylate grafted starch and 0-1% of hydroxyethyl acrylate/acryloyl dimethyl sodium taurate copolymer. Xanthan gum 0-1%, and water in balance.
The component B comprises the following raw materials in percentage by weight:
0-2% of polydimethylsiloxane, 0-20% of PEG-100 glyceryl stearate, 0-4% of C14-22 alcohol, 0-6% of C12-20 alkyl glucoside, 0-10% of cetearyl alcohol, 0-30% of olive oil, 0-10% of stearic acid, 0-30% of cyclopentadecyl polysiloxane and polydimethylsiloxane cross-linked polymer, 0-4% of p-hydroxyacetophenone, 0-10% of potassium cetyl phosphate, and the balance of petrolatum.
The component C comprises the following raw materials in percentage by weight:
0-50% of ligusticum chuanxiong hort oil and the balance of 1, 2-hexanediol.
The component D comprises the following raw materials in percentage by weight:
0-15% of borneol, 0-15% of propylene glycol and the balance of menthol.
The component E comprises the following raw materials in percentage by weight:
CI 162550-35%, CI 191400-35%, the remainder is caramel color.
The component E comprises the following raw materials in percentage by weight:
0-12% of dendrobium officinale extract, 0-12% of butterflybush flower extract, 0-12% of cassia tora seed extract, 0-12% of phellodendron amurense extract, 0-12% of medlar extract, 0-12% of salvia miltiorrhiza extract, 0-12% of chamomile flower extract and the balance pyridoxine.
The preparation method of the eye cream comprises the following steps:
(1) adding the component A into an emulsifying pot, stirring, heating to 80-85 deg.C, homogenizing for 2-5min at 20-40 Hz;
(2) adding the component B into an emulsifying pot, homogenizing for 4-6min at 30-50Hz, maintaining at 3-5 deg.C for 20-40min, vacuumizing to-0.06-0.08 MPa, and cooling;
(3) cooling to 40-45 deg.C, sequentially adding C, D, F components, and stirring;
(4) adding component E to match colors with the plate, inspecting after color matching, filtering with 200-mesh filter cloth after qualification, and discharging.
The invention has the advantages that:
the eye protection cream has the beneficial effects that the eye protection cream has the effects of nourishing and moistening eyes, clearing liver and improving eyesight, dispelling wind and resisting inflammation, and promoting blood circulation and removing obstruction in channels, can relieve eye fatigue symptoms such as eye dryness, eye astringency and eye distending pain caused by various eye diseases, and comprehensively care eye health;
the eye protection cream disclosed by the invention is convenient to use, does not contain a preservative, is high in applicability, does not cause allergic reaction on any skin, and is mild in use.
Detailed Description
Example 1
An eye-protecting ointment, which comprises A, B, C, D, E, F five components.
The component A comprises the following raw materials in percentage by weight:
10% of glycerol, 5% of sodium polyacrylate grafted starch and 1% of hydroxyethyl acrylate/acryloyl dimethyl sodium taurate copolymer. Xanthan gum 1%, the remainder being water.
The component B comprises the following raw materials in percentage by weight:
2% of polydimethylsiloxane, 20% of PEG-100 glyceryl stearate, 4% of C14-22 alcohol, 6% of C12-20 alkyl glucoside, 10% of cetearyl alcohol, 30% of olive oil, 10% of stearic acid, 30% of cyclopentadecyl dimethicone and dimethicone crosspolymer, 4% of p-hydroxyacetophenone, 10% of potassium cetyl phosphate, and the balance petrolatum.
The component C comprises the following raw materials in percentage by weight:
50% of ligusticum chuanxiong hort oil and 50% of 1, 2-hexanediol.
The component D comprises the following raw materials in percentage by weight:
15% of borneol, 15% of propylene glycol and 70% of menthol.
The component E comprises the following raw materials in percentage by weight:
CI 1625535%, CI 1914035% and caramel color 30%.
The component E comprises the following raw materials in percentage by weight:
12% of dendrobium officinale extract, 12% of butterflybush flower extract, 12% of cassia tora seed extract, 12% of phellodendron amurense extract, 12% of medlar extract, 12% of salvia miltiorrhiza extract, 12% of chamomile extract and the balance pyridoxine.
The preparation method of the eye cream comprises the following steps:
(1) adding the component A into an emulsifying pot, stirring uniformly, heating to 85 deg.C, and homogenizing for 5min at homogenizing frequency of 40 Hz;
(2) adding the component B into an emulsifying pot, homogenizing for 6min at 50Hz, keeping the temperature at 5 deg.C for 40min, and starting to cool under 0.08 MPa;
(3) cooling to 45 ℃, sequentially adding C, D, F components, and uniformly stirring;
(4) adding component E to match colors with the plate, inspecting after color matching, filtering with 200-mesh filter cloth after qualification, and discharging.
Example 2
An eye-protecting ointment, which comprises A, B, C, D, E, F five components.
The component A comprises the following raw materials in percentage by weight:
1% of glycerol, 5% of sodium polyacrylate grafted starch, 1% of hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, 1% of xanthan gum and the balance of water.
The component B comprises the following raw materials in percentage by weight:
1% of polydimethylsiloxane, 1% of PEG-100 glyceryl stearate, 1% of C14-22 alcohol, 1% of C12-20 alkyl glucoside, 1% of cetearyl alcohol, 1% of olive oil, 1% of stearic acid, 1% of cyclopentadecyl dimethicone and dimethicone crosspolymer, 1% of p-hydroxyacetophenone, 1% of potassium cetyl phosphate, and the balance petrolatum.
The component C comprises the following raw materials in percentage by weight:
1% of ligusticum chuanxiong hort oil and 99% of 1, 2-hexanediol.
The component D comprises the following raw materials in percentage by weight:
1% of borneol, 1% of propylene glycol and 98% of menthol.
The component E comprises the following raw materials in percentage by weight:
CI 162551%, CI 191401% and caramel color 98%.
The component E comprises the following raw materials in percentage by weight:
1% of dendrobium officinale extract, 1% of butterflybush flower extract, 1% of cassia tora seed extract, 1% of phellodendron amurense extract, 1% of medlar extract, 1% of salvia miltiorrhiza extract, 1% of chamomile extract and the balance pyridoxine.
The preparation method of the eye cream comprises the following steps:
(1) adding the component A into an emulsifying pot, stirring uniformly, heating to 85 deg.C, and homogenizing for 5min at homogenizing frequency of 40 Hz;
(2) adding the component B into an emulsifying pot, homogenizing for 6min at 50Hz, keeping the temperature at 5 deg.C for 40min, and starting to cool under-0.06 Mpa;
(3) cooling to 45 ℃, sequentially adding C, D, F components, and uniformly stirring;
(4) adding component E to match colors with the plate, inspecting after color matching, filtering with 200-mesh filter cloth after qualification, and discharging.
Example 3
An eye-protecting ointment, which comprises A, B, C, D, E, F five components.
The component A comprises the following raw materials in percentage by weight:
10% of glycerol, 3% of sodium polyacrylate grafted starch and 87% of water.
The component B comprises the following raw materials in percentage by weight:
PEG-100 glyceryl stearate 1%, C14-22 alcohol 4%, C12-20 alkyl glucoside 3%, cetearyl alcohol 2%, olive oil 5%, stearic acid 2%, cyclopentadecyl dimethyl siloxane and dimethicone crosspolymer 3%, p-hydroxyacetophenone 1%, cetyl phosphate potassium 2%, the remainder being petrolatum.
The component C comprises the following raw materials in percentage by weight:
20% of ligusticum chuanxiong hort oil and 80% of 1, 2-hexanediol.
The component D comprises the following raw materials in percentage by weight:
15% of borneol and 85% of menthol.
The component E comprises the following raw materials in percentage by weight:
CI 1914015% and caramel color 85%.
The component E comprises the following raw materials in percentage by weight:
5% of dendrobium officinale extract, 2% of phellodendron amurense extract, 7% of chamomile extract and the balance of pyridoxine.
The preparation method of the eye cream comprises the following steps:
(1) adding the component A into an emulsifying pot, stirring uniformly, heating to 84 ℃, and homogenizing for 4min at the homogenizing frequency of 30 Hz;
(2) adding the component B into an emulsifying pot, homogenizing for 5min at a homogenizing frequency of 40Hz, then keeping the temperature at 4 ℃ for 30min, starting vacuum at 0.07Mpa, and cooling;
(3) cooling to 40 ℃, sequentially adding C, D, F components, and uniformly stirring;
(4) adding component E to match colors with the plate, inspecting after color matching, filtering with 200-mesh filter cloth after qualification, and discharging.
And (3) performance testing:
eye fatigue relief test
200 volunteers were selected and randomly divided into four groups of 50 persons each for eye fatigue relief observation experiments. The eye protection ointments prepared in the first embodiment, the second embodiment and the third embodiment and the commercially available eye protection ointments (Yuguanbaicao eye protection ointments) are respectively used for the volunteers to continuously learn before computers and have symptoms such as eye fatigue and dryness after working for 5 hours.
The experimental results are as follows:
| item | Dry and astringent condition | Has no irritation |
| Example A product | Mitigation | Is free of |
| EXAMPLE two products | Mitigation | Is free of |
| EXAMPLE three products | Mitigation | Is free of |
| Eye cream on the market | Mitigation | Slight discomfort |
Claims (8)
1. An eye-protecting ointment is characterized by comprising A, B, C, D, E, F five components.
2. The eye-protecting cream of claim 1, wherein the component A comprises the following raw materials in percentage by weight:
0-10% of glycerol, 0-5% of sodium polyacrylate grafted starch, 0-1% of hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, 0-1% of xanthan gum and the balance of water.
3. The eye-protecting cream of claim 1, wherein the component B comprises the following raw materials in percentage by weight:
0-2% of polydimethylsiloxane, 0-20% of PEG-100 glyceryl stearate, 0-4% of C14-22 alcohol, 0-6% of C12-20 alkyl glucoside, 0-10% of cetearyl alcohol, 0-30% of olive oil, 0-10% of stearic acid, 0-30% of cyclopentadecyl polysiloxane and polydimethylsiloxane cross-linked polymer, 0-4% of p-hydroxyacetophenone, 0-10% of potassium cetyl phosphate, and the balance of petrolatum.
4. The eye-protecting cream of claim 1, wherein the component C comprises the following raw materials in percentage by weight:
0-50% of ligusticum chuanxiong hort oil and the balance of 1, 2-hexanediol.
5. The eye-protecting cream of claim 1, wherein the component D comprises the following raw materials in percentage by weight:
0-15% of borneol, 0-15% of propylene glycol and the balance of menthol.
6. The eye-protecting cream of claim 1, wherein the component E comprises the following raw materials in percentage by weight:
CI 162550-35%, CI 191400-35%, the remainder is caramel color.
7. The eye-protecting cream of claim 1, wherein the component E comprises the following raw materials in percentage by weight:
0-12% of dendrobium officinale extract, 0-12% of butterflybush flower extract, 0-12% of cassia tora seed extract, 0-12% of phellodendron amurense extract, 0-12% of medlar extract, 0-12% of salvia miltiorrhiza extract, 0-12% of chamomile flower extract and the balance pyridoxine.
8. The eye cream according to any one of claims 1 to 7, wherein the eye cream is prepared by a method comprising the steps of:
(1) adding the component A into an emulsifying pot, stirring, heating to 80-85 deg.C, homogenizing for 2-5min at 20-40 Hz;
(2) adding the component B into an emulsifying pot, homogenizing for 4-6min at 30-50Hz, maintaining at 3-5 deg.C for 20-40min, vacuumizing to-0.06-0.08 MPa, and cooling;
(3) cooling to 40-45 deg.C, sequentially adding C, D, F components, and stirring;
(4) adding component E to match colors with the plate, inspecting after color matching, filtering with 200-mesh filter cloth after qualification, and discharging.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010916594.6A CN111991511A (en) | 2020-09-03 | 2020-09-03 | Eye protection cream |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010916594.6A CN111991511A (en) | 2020-09-03 | 2020-09-03 | Eye protection cream |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111991511A true CN111991511A (en) | 2020-11-27 |
Family
ID=73465361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010916594.6A Pending CN111991511A (en) | 2020-09-03 | 2020-09-03 | Eye protection cream |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111991511A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113069373A (en) * | 2021-04-06 | 2021-07-06 | 邵毅 | Dry eye cream, preparation method and application |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285078A (en) * | 2013-05-31 | 2013-09-11 | 吴克 | Comfortable cream |
| CN103961556A (en) * | 2014-04-28 | 2014-08-06 | 广西健宝石斛有限责任公司 | Dendrobium officinale oculentum for relieving asthenopia |
| CN106728530A (en) * | 2017-03-22 | 2017-05-31 | 陈顶凯 | The preparation method of eye sticker |
| CN107007529A (en) * | 2017-04-19 | 2017-08-04 | 陆露梅 | A kind of eyeshield cream |
| CN107510736A (en) * | 2016-06-15 | 2017-12-26 | 陕西新视明医药生物科技有限公司 | The Chinese medicine composition of eye strain is alleviated in a kind of external application |
| CN107982171A (en) * | 2017-12-15 | 2018-05-04 | 广东盛美化妆品有限公司 | A kind of celestial grass lotion of the Herba Dendrobii extract containing iron sheet and preparation method thereof |
| CN108853353A (en) * | 2018-08-06 | 2018-11-23 | 北京朗之星生物科技有限公司 | Have effects that protect active compound, preparation method and its application of eyesight |
| CN109200196A (en) * | 2018-11-09 | 2019-01-15 | 浙江省医学科学院 | Dendrobium stem alkali eye patch and preparation method thereof |
| CN109498695A (en) * | 2019-01-10 | 2019-03-22 | 开封御创医学科技有限公司 | A kind of small-micelle water extraction Chinese herb medicine eye paste formula and its preparation process |
| CN109646182A (en) * | 2019-02-26 | 2019-04-19 | 上海雨桐生物科技有限公司 | A kind of Chinese medicine eyeshield hot compress eye-mask and its pack formula |
-
2020
- 2020-09-03 CN CN202010916594.6A patent/CN111991511A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285078A (en) * | 2013-05-31 | 2013-09-11 | 吴克 | Comfortable cream |
| CN103961556A (en) * | 2014-04-28 | 2014-08-06 | 广西健宝石斛有限责任公司 | Dendrobium officinale oculentum for relieving asthenopia |
| CN107510736A (en) * | 2016-06-15 | 2017-12-26 | 陕西新视明医药生物科技有限公司 | The Chinese medicine composition of eye strain is alleviated in a kind of external application |
| CN106728530A (en) * | 2017-03-22 | 2017-05-31 | 陈顶凯 | The preparation method of eye sticker |
| CN107007529A (en) * | 2017-04-19 | 2017-08-04 | 陆露梅 | A kind of eyeshield cream |
| CN107982171A (en) * | 2017-12-15 | 2018-05-04 | 广东盛美化妆品有限公司 | A kind of celestial grass lotion of the Herba Dendrobii extract containing iron sheet and preparation method thereof |
| CN108853353A (en) * | 2018-08-06 | 2018-11-23 | 北京朗之星生物科技有限公司 | Have effects that protect active compound, preparation method and its application of eyesight |
| CN109200196A (en) * | 2018-11-09 | 2019-01-15 | 浙江省医学科学院 | Dendrobium stem alkali eye patch and preparation method thereof |
| CN109498695A (en) * | 2019-01-10 | 2019-03-22 | 开封御创医学科技有限公司 | A kind of small-micelle water extraction Chinese herb medicine eye paste formula and its preparation process |
| CN109646182A (en) * | 2019-02-26 | 2019-04-19 | 上海雨桐生物科技有限公司 | A kind of Chinese medicine eyeshield hot compress eye-mask and its pack formula |
Non-Patent Citations (1)
| Title |
|---|
| 付玲,等: "HPLC法测定眼明熏洗液中阿魏酸含量", 《新疆医科大学学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113069373A (en) * | 2021-04-06 | 2021-07-06 | 邵毅 | Dry eye cream, preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110859762B (en) | Gel containing Camellia japonica extract and having after-sun repair effect and preparation method thereof | |
| CN109771348B (en) | Whitening, moisturizing and wrinkle-removing face cream rich in natural product extract components and preparation method thereof | |
| CN111329811A (en) | Moisturizing and repairing essence milk and preparation method thereof | |
| CN111067820A (en) | Plant repair essence milk and preparation method thereof | |
| CN111991511A (en) | Eye protection cream | |
| CN111407698A (en) | Wrinkle-removing moisturizing skin care lotion and preparation method thereof | |
| CN109431943B (en) | Repairing paste for infantile eczema and preparation thereof | |
| CN108295022B (en) | Acne-removing composition and preparation method thereof | |
| CN113116775A (en) | Acne-removing gel mask and preparation process thereof | |
| CN105030620A (en) | Moisturizing and acne removing facial cleanser and preparing method thereof | |
| CN112716842A (en) | Organic moisturizing cream with long-acting moisturizing effect and preparation method thereof | |
| CN111991316A (en) | Anti-allergy repairing composition and preparation method and application thereof | |
| CN110974775A (en) | Allergy-relieving composition containing nostoc sphaeroides and preparation method and application thereof | |
| CN103463333B (en) | Aloe-cactus-peach leaf gel preparation and preparation method thereof | |
| CN115282188A (en) | Composite essential oil composition containing lavender essential oil and preparation method thereof | |
| CN113925828A (en) | Borneol eye lotion | |
| CN113730341A (en) | Bitong gel and using method and preparation method thereof | |
| CN109431881B (en) | Tibetan sheep oil for preventing skin from being cracked due to dryness | |
| CN112402356A (en) | Pure micro-ecological skin cooling and nursing mask containing Chinese herbal medicines | |
| US20080171097A1 (en) | Product liquorice root and oak bark in combination with dexapanthenol | |
| CN112891439A (en) | Compound pipewort liquid | |
| CN104815155A (en) | Traditional Chinese medicine drops capable of expelling wind, relieving itching and improving eyesight | |
| CN103330765B (en) | Cactus-peach leaf gel preparation and preparation method thereof | |
| CN109432290B (en) | Traditional Chinese medicine composition with skin anti-allergy effect and aqueous extract and fermentation product and application thereof | |
| CN115671239B (en) | Anti-inflammatory, detumescence, antibacterial, antipruritic, anticracking and repairing jelly-curing cream and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: Room 102, building 30, Yinhu Science Park, 15 Fuxian Road, Yinhu street, Fuyang District, Hangzhou City, Zhejiang Province 310000 Applicant after: Zhejiang muzhongming Biotechnology Co.,Ltd. Address before: 310000 room 3701-4, building 2, Wangjing business center, ningwei street, Xiaoshan District, Hangzhou City, Zhejiang Province Applicant before: Zhejiang muzhongming Biotechnology Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20211029 Address after: 310000 Room 203, No. 2, Tianyuan Road, Fuchun street, Fuyang City, Hangzhou City, Zhejiang Province Applicant after: Li Haihua Address before: Room 102, building 30, Yinhu Science Park, 15 Fuxian Road, Yinhu street, Fuyang District, Hangzhou City, Zhejiang Province 310000 Applicant before: Zhejiang muzhongming Biotechnology Co.,Ltd. |